117TH CONGRESS 
1ST SESSION H. R. 1193 
AN ACT 
To amend title IV of the Public Health Service Act to 
direct the Director of the National Institutes of Health, 
in consultation with the Director of the National Heart, 
Lung, and Blood Institute, to establish a program under 
which the Director of the National Institutes of Health 
shall support or conduct research on valvular heart dis-
ease, and for other purposes.
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Cardiovascular Ad-
vances in Research and Opportunities Legacy Act’’. 
SEC. 2. GRANTS FOR VALVULAR HEART DISEASE RE-
SEARCH. 
Subpart 2 of part C of title IV of the Public Health 
Service Act (42 U.S.C. 285b et seq.) is amended by insert-
ing after section 424C (42 U.S.C. 285b–7c) the following: 
‘‘SEC. 424D. GRANTS FOR VALVULAR HEART DISEASE RE-
SEARCH. 
‘‘(a) IN GENERAL.—The Director of the National In-
stitutes of Health, in consultation with the Director of the 
Institute, shall support or conduct research regarding val-
vular heart disease. 
‘‘(b) SUPPORT GUIDELINES.—The distribution of 
funding authorized under subsection (a) may be used to 
pursue the following outcomes: 
‘‘(1) Using precision medicine and advanced 
technological imaging to generate data on individ-
uals with valvular heart disease. 
‘‘(2) Identifying and developing a cohort of in-
dividuals with valvular heart disease and available 
data.
‘‘(3) Corroborating data generated through clin-
ical trials to develop a prediction model to distin-
guish individuals at high risk for sudden cardiac ar-
rest or sudden cardiac death from valvular heart dis-
ease. 
‘‘(4) For other outcomes needed to acquire nec-
essary data on valvular heart disease. 
‘‘(c) MITRAL VALVE PROLAPSE WORKSHOP.—Not 
later than one year after the date of the enactment of this 
section, the Director of the Institute shall convene a work-
shop composed of subject matter experts and stakeholders 
to identify research needs and opportunities to develop 
prescriptive guidelines for treatment of individuals with 
mitral valve prolapse. 
‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—For the 
purpose of carrying out this section, there is authorized 
to be appropriated $20,000,000 for each of fiscal years 
2022 through 2026.’’. 
SEC. 3. PROGRAMS OF CENTERS FOR DISEASE CONTROL 
AND PREVENTION. 
Part B of title III of the Public Health Service Act 
(42 U.S.C. 243 et seq.) is amended by inserting after sec-
tion 312 the following section:
‘‘SEC. 312A. PREVENTION OF SUDDEN CARDIAC DEATH AS A 
RESULT OF VALVULAR HEART DISEASE. 
‘‘(a) IN GENERAL.—The Secretary, acting through 
the Director of the Centers for Disease Control and Pre-
vention, may carry out projects to increase education, 
awareness, or diagnosis of valvular heart disease and to 
reduce the incidence of sudden cardiac death caused by 
valvular heart disease. Such projects may be carried out 
by the Secretary directly or through awards of grants or 
contracts to public or nonprofit private entities. The Sec-
retary may directly (or through such awards) provide tech-
nical assistance with respect to the planning, development, 
and operation of such projects. 
‘‘(b) CERTAIN ACTIVITIES.—Upon availability of ap-
plicable data, projects carried out under subsection (a) 
may include— 
‘‘(1) continuing the activities at the Division for 
Heart Disease and Stroke Prevention, including 
those related to valvular heart disease; 
‘‘(2) broadening the awareness of the public 
concerning the risk factors for, the symptoms of, 
and the public health consequences of valvular heart 
disease; and 
‘‘(3) enhancing surveillance of out-of-hospital 
cardiac arrests to improve patient outcomes.
‘‘(c) GRANT PRIORITIZATION.—The Secretary may, 
in awarding grants or entering into contracts pursuant to 
subsection (a), give priority to entities seeking to carry 
out projects that target populations most impacted by val-
vular heart disease. 
‘‘(d) COORDINATION OF ACTIVITIES.—The Secretary 
shall ensure that activities under this section are coordi-
nated, as appropriate, with other agencies of the Public 
Health Service that carry out activities regarding valvular 
heart disease. 
‘‘(e) BEST
PRACTICES.—The Secretary, acting 
through the Director of the Centers for Disease Control 
and Prevention, shall— 
‘‘(1) collect and analyze the findings of research 
conducted with respect to valvular heart disease; and 
‘‘(2) taking into account such findings, publish 
on the website of the Centers for Disease Control 
and Prevention best practices for physicians and 
other health care providers who provide care to indi-
viduals with valvular heart disease.’’. 
Passed the House of Representatives December 8, 
2021. 
Attest: 
Clerk.